EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)

Jinghao Pan, Boyang Li, Ruonan Lin, Chenlu Fang, Lucy Yue Lau, Zehao Hong, Yi Chen

International Journal of Oncology · 2026

DOI: 10.3892/ijo.2026.5932 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, 2026. Verfasst von Jinghao Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China. Hauptthemen laut MEDLINE: Neoplasms, Protein Processing, Post-Translational, Biomarkers, Tumor, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune escape and therapeutic resistance remain major obstacles to durable benefit from cancer immunotherapy, yet transcript‑based or abundance‑based biomarkers often fail to capture the regulatory states that determine effective immune control. Post‑translational modifications (PTMs) form a dynamic protein‑state layer that rapidly reshapes protein stability, trafficking, complex assembly, and signaling persistence under tumor‑intrinsic and therapy‑imposed stress. In the present review, a biomarker‑oriented framework is proposed in which PTM biology is interpreted through three recurrent immune constraints: Checkpoint competence, tumor visibility and stress‑conditioned immune‑state programming. Within this framework, programmed death‑ligand 1 is viewed as a protein‑state biomarker problem rather than a static expression marker; tumor visibility is defined by durable antigen‑presentation competence and interferon‑linked reinforcement; and stress‑driven immune dysfunction is interpreted through metabolite‑sensitive PTM rewiring and chromatin‑coupled suppressive stabilization. Rather than cataloguing PTMs comprehensively in cancer immunity, the present review focuses on five core exemplar PTM axes, glycosylation, palmitoylation, ubiquitin editing, phosphorylation and lactylation, because they repeatedly map to rate‑limiting immune constraints, are supported by mechanistic evidence, and represent candidate assay‑compatible or intervention‑relevant state variables at differing levels of translational maturity. It is further outlined how integrated proteogenomic, immuno‑peptidomic, and spatial datasets can be used to discover candidate PTM‑state biomarkers, validate mechanism‑proximal readouts in prespecified pretreatment and on‑treatment settings, and prioritize single or co‑dominant state constraints for patient stratification, pharmacodynamic monitoring, and rational combination design. By organizing PTM biology around measurable state variables rather than modification class alone, the present review provides a phase‑aware translational framework for candidate biomarker discovery, fit‑for‑purpose validation, constraint‑guided stratification, and therapeutic prioritization in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProtein Processing, Post-TranslationalBiomarkers, TumorImmunotherapyHumansDrug Resistance, NeoplasmAnimalsTumor Escape

Stichwörter der Autor:innen

biomarkerscancer immunityimmunotherapy resistancepost‑translational modificationsprogrammed death‑ligand 1tumor visibility

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
  • Department of Public Health, Harvard Medical School, Boston, MA 02115, USA.
  • Cancer Research Institute, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830011, P.R. China.

Zitieren

APA

Pan, J., Li, B., Lin, R., Fang, C., Lau, L. Y., Hong, Z., & Chen, Y. (2026). Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2026.5932

Vancouver

Pan J, Li B, Lin R, Fang C, Lau LY, Hong Z, et al. Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review). International Journal of Oncology. 2026. doi:10.3892/ijo.2026.5932

BibTeX
@article{Pan2026,
  author = {Pan, Jinghao and Li, Boyang and Lin, Ruonan and Fang, Chenlu and Lau, Lucy Yue and Hong, Zehao and Chen, Yi},
  title = {Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)},
  journal = {International Journal of Oncology},
  year = {2026},
  doi = {10.3892/ijo.2026.5932}
}
Kostenlos starten →